Bulletin
Investor Alert

Cannabis Watch Archives | Email alerts

Feb. 7, 2019, 7:48 a.m. EST

Cronos stock downgraded after rocketing more than 100% in 2019 so far

GMP Securities cuts rating to hold from buy after stock run-up, but says it’s still a believer in the Cronos story

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Cronos Group Inc. (CRON)
  • X
    Horizons Marijuana Life Sciences Index ETF (HMMJ)
  • X
    Altria Group Inc. (MO)

or Cancel Already have a watchlist? Log In

By Ciara Linnane, MarketWatch


Getty Images

Cannabis stocks were mostly lower on Tuesday, as investors digested a downgrade of Canada’s Cronos Group Inc. after its strong gains in the year so far.

Cronos shares /zigman2/quotes/206842762/composite CRON -3.92% were down 6%, after GMP Securities lowered its rating to hold from buy and reiterated a stock price target of C$24 ($18) that implies 21% downside from its current trading level.

“The company’s shares have surged ~110% year-to-date on no material news and have outperformed the HMMJ cannabis index /zigman2/quotes/208856346/delayed CA:HMMJ -3.41%  by a factor of 2,” analyst Martin Landry wrote in the note. “This strong performance forces us to change our rating to HOLD solely based on valuation.”

GMP is a believer in the’ promising outlook at Cronos, praising its strong management team and record of efficient capital deployment. The recent news of tobacco giant Altria Inc.’s /zigman2/quotes/208895754/composite MO +1.49%  planned C$2.4 billion investment in the company “will be a game changer,” Landry wrote in a note.

However, “Cronos is still in the early stage of its development with limited revenues in relation to its sizable market cap,” said Landry. “Hence, in our view, the company needs to backfill its valuation with capital deployment into the U.S. market, increase its penetration in the Canadian recreational market and continue its international expansion.”

The analyst is advising investors to take a breather on the stock and wait for a more attractive entry point.

Also Tuesday, a new report on American’s changing views of cannabis found public opinion has shifted dramatically in favor of legalization, a trend it partially credited to the media.

Read here: This is the surprising reason why Americans have dramatically shifted their views on legalizing pot

“As politically polarized as the country may seem, when it comes to marijuana, Americans have been changing their attitudes together, as a nation,” the report published by research database The Conversation found.

Support for legalization began to climb as the media began to cover cannabis as a medical issue, disassociating it from other Schedule I drugs such as heroin and cocaine with which it is still classified. As Americans became more supportive of the substance, they became less punitive about its use and began to view the criminal justice system as overly harsh.

Meanwhile, the decline in the number of Americans who say they have a religious affiliation also contributed to overall support, the study found. It did not find a drastic increase in the number of users of cannabis in the U.S.

Namaste Technologies Inc. /zigman2/quotes/204114873/delayed NXTFF -43.50%  shares rose 1%. The stock fell about 16% on Monday after it fired its chief executive for cause and launched a review of its strategic options that may result in a sale of the company.

The company said a special committee probe found evidence of self-dealing and other breaches of fiduciary duty by Sean Dollinger and has launched legal action seeking damages and disgorgement.

The U.S. Securities and Exchange Commission has warned of a potentially elevated risk of scams and other suspicious behavior in the relatively nascent cannabis industry.

Tetra Bio-Pharma Inc. /zigman2/quotes/210370082/delayed TBPMF -0.45%  shares slid 21%, after it said it was temporarily suspending a phase 3 clinical program because of impurities it discovered in its PPP001 investigational drug, which is made of raw cannabis materials and is being given to patients. The company said it informed regulators within 24-hours of discovering the impurities and has notified all patients involved.

/zigman2/quotes/206842762/composite
US : U.S.: Nasdaq
$ 5.64
-0.23 -3.92%
Volume: 5.99M
Aug. 7, 2020 4:00p
P/E Ratio
12.27
Dividend Yield
N/A
Market Cap
$1.97 billion
Rev. per Employee
$55,248
loading...
/zigman2/quotes/208856346/delayed
CA : Canada: Toronto
$ 6.79
-0.24 -3.41%
Volume: 270,495
Aug. 7, 2020 3:58p
loading...
/zigman2/quotes/208895754/composite
US : U.S.: NYSE
$ 42.17
+0.62 +1.49%
Volume: 5.62M
Aug. 7, 2020 4:03p
P/E Ratio
N/A
Dividend Yield
8.16%
Market Cap
$78.37 billion
Rev. per Employee
$2.36M
loading...
/zigman2/quotes/204114873/delayed
US : U.S.: OTC
$ 0.02
-0.02 -43.50%
Volume: 0.00
Aug. 3, 2020 9:50a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$632,581
Rev. per Employee
N/A
loading...
/zigman2/quotes/210370082/delayed
US : U.S.: OTC
$ 0.15
-0.0007 -0.45%
Volume: 141,139
Aug. 7, 2020 3:30p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$42.94 million
Rev. per Employee
N/A
loading...
1 2
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.